Addressing a lingering question in the field, the SPIRIT OF ARTEMIS trial shows that using a higher weight-adjusted dose of heparin during transradial coronary angiography staves off radial artery ...

CHICAGO, IL — A small, single-center analysis suggests that it may be time to increase the recommended maximum, weight-based unfractionated-heparin bolus and infusion doses for patients with ACS so as ...

Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...

Speaking with heart wire, Kearon noted there was indirect evidence suggesting that APTT monitoring didn't help improve the efficacy or safety of using unfractionated heparin if the patient had been ...

Collaborative international clinical trials testing full dose anticoagulation with heparin (a blood thinner) in both moderately ill and critically ill patients has found the treatment improves ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Therapeutic-dose low-molecular-weight heparin decreased ...

low-dose subcutaneous heparin, although safer than warfarin, was ineffective for the prevention of venous thrombosis Given that low-dose subcutaneous heparin, although safer than warfarin, was ...

Please provide your email address to receive an email when new articles are posted on . Early administration of full-dose heparin slowed the thrombo-inflammatory process and reduced the risk for ...

Baxter Healthcare has temporarily stopped manufacturing multi-dose vials of heparin sodium for injection due to reports of serious allergic reactions and hypotension in patients who receive high bolus ...

The anti-coagulant heparin reduces the likelihood of death from COVID-19 by 78% when administered in therapeutic doses to patients with signs of respiratory failure on admission to hospital, according ...

Heparin entered clinical testing in the 1930s and, in combination with a vitamin K antagonist, was shown in the 1950s to be effective in the treatment of acute pulmonary embolism (MILESTONE 3).